Bifunctional Furo[2,3-d]pyrimidine Compounds for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges with multidrug resistance and the need for combination chemotherapy, which can lead to drug interactions and toxicities, highlighting the need for single agents that simultaneously target multiple pathways effectively.
Innovation Solution
Development of conformationally restricted bicyclic furo[2,3-d]pyrimidine compounds that act as both receptor tyrosine kinase inhibitors and microtubule inhibitors, designed to overcome resistance mechanisms and minimize side effects by targeting multiple pathways simultaneously.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination chemotherapy is used to treat cancer, then the effectiveness against multiple resistance mechanisms is improved, but the drug interactions and toxicities increase
Solution Approach 1:
The patent merges two distinct therapeutic functions (RTK inhibition and microtubule destabilization) into a single bifunctional compound. The molecule contains both a RTK inhibitor moiety and a microtubule destabilizing moiety connected by a linker, enabling simultaneous targeting of multiple pathways while avoiding the need for separate combination therapies and their associated toxicities
Solution Approach 2:
The invention creates a universal compound that performs multiple functions: it acts as both a receptor tyrosine kinase inhibitor and a microtubule destabilizing agent. This multi-functional design allows a single agent to address multiple resistance mechanisms that would otherwise require separate drugs
2Object-affected harmful factors
If single agents are used to simplify treatment, then the drug interactions and toxicities are reduced, but the ability to overcome multidrug resistance simultaneously is limited
Solution Approach 1:
The patent combines multiple therapeutic modalities (RTK inhibition and microtubule destabilization) within a single molecular entity, allowing the compound to overcome multiple resistance mechanisms simultaneously while maintaining the benefits of single-agent therapy
3Strength
If conventional microtubule targeting agents are used, then the microtubule depolymerization effect is achieved, but the multidrug resistance mediated by P-glycoprotein and III tubulin is not overcome
Solution Approach 1:
The compound is segmented into distinct functional moieties: a microtubule destabilizing portion that overcomes resistance mechanisms and a RTK inhibitor portion that provides additional therapeutic activity. This segmentation allows each moiety to perform its specific function independently while working synergistically
Data Source
AI summary
The present invention provides conformationally restricted 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidine compounds and pharmaceutical compositions comprising these compounds. Preferably, the compounds exhibit dual inhibition of microtubule assembly and receptor tyrosine kinases. Methods of treating cancer comprising administering a therapeutically effective amount of at least one conformationally restricted 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidine compound to a patient is disclosed.